Spencer B Gibson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7238172/publications.pdf

Version: 2024-02-01

121 papers	20,003 citations	47006 47 h-index	21540 114 g-index
122 all docs	122 docs citations	122 times ranked	32800 citing authors

#	Article	IF	Citations
1	Autophagy inhibition by TSSC4 (tumor suppressing subtransferable candidate 4) contributes to sustainable cancer cell growth. Autophagy, 2022, 18, 1274-1296.	9.1	11
2	Tumor Suppressing Subtransferable Candidate 4 Expression Prevents Autophagy-Induced Cell Death Following Temozolomide Treatment in Glioblastoma Cells. Frontiers in Cell and Developmental Biology, 2022, 10, 823251.	3.7	2
3	Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells. Cancers, 2021, 13, 1038.	3.7	14
4	Altered T Follicular Helper Cell Subsets and Function in Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2021, 11, 674492.	2.8	9
5	Reactive Oxygen Species (ROS) Regulates Different Types of Cell Death by Acting as a Rheostat. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-17.	4.0	104
6	Three dimensions of autophagy in regulating tumor growth: cell survival/death, cell proliferation, and tumor dormancy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166265.	3.8	17
7	Misoprostol treatment prevents hypoxia-induced cardiac dysfunction through a 14-3-3 and PKA regulatory motif on Bnip3. Cell Death and Disease, 2021, 12, 1105.	6.3	7
8	Antihistamines are synergistic with Brutonâ€™s tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells. Leukemia Research, 2020, 96, 106423.	0.8	5
9	Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment. Cancers, 2020, 12, 650.	3.7	19
10	Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival. Leukemia and Lymphoma, 2019, 60, 3204-3213.	1.3	23
11	Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia. Cancers, 2019, 11, 1519.	3.7	5
12	Lysosomal Destabilizing Drug Siramesine and the Dual Tyrosine Kinase Inhibitor Lapatinib Induce a Synergistic Ferroptosis through Reduced Heme Oxygenase-1 (HO-1) Levels. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-14.	4.0	49
13	Buccal cell telomere length is not a useful marker for comorbidities in chronic lymphocytic leukemia. Leukemia Research, 2019, 86, 106220.	0.8	1
14	Expression and function of phosphoinositide 3â€kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow. British Journal of Haematology, 2019, 185, 883-887.	2.5	5
15	IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia. Blood Advances, 2019, 3, 2188-2198.	5.2	18
16	A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL). Leukemia and Lymphoma, 2019, 60, 980-989.	1.3	8
17	Distinct roles for phosphoinositide 3-kinases Î³ and Î´ in malignant B cell migration. Leukemia, 2018, 32, 1958-1969.	7.2	40
18	Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies. Apoptosis: an International Journal on Programmed Cell Death, 2018, 23, 93-112.	4.9	44

#	Article	IF	Citations
19	Identification and Characterization of Novel Receptor-Interacting Serine/Threonineâ€Protein Kinase 2 Inhibitors Using Structural Similarity Analysis. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 354-367.	2.5	22
20	The BH3 only Bcl-2 family member BNIP3 regulates cellular proliferation. PLoS ONE, 2018, 13, e0204792.	2.5	19
21	Harnessing Oxidative Stress as an Innovative Target for Cancer Therapy. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-2.	4.0	29
22	Antimalarial drugs trigger lysosome-mediated cell death in chronic lymphocytic leukemia (CLL) cells. Leukemia Research, 2018, 70, 79-86.	0.8	17
23	A novel spliced variant of the TIN2 shelterin is present in chronic lymphocytic leukemia. Leukemia Research, 2017, 59, 66-74.	0.8	5
24	The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. Leukemia and Lymphoma, 2017, 58, 1358-1365.	1.3	35
25	EGFR Family Membersâ€™ Regulation of Autophagy Is at a Crossroads of Cell Survival and Death in Cancer. Cancers, 2017, 9, 27.	3.7	73
26	Lysosomes as Oxidative Targets for Cancer Therapy. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-8.	4.0	93
27	Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells. PLoS ONE, 2017, 12, e0182921.	2.5	136
28	Tyrosine kinase receptor EGFR regulates the switch in cancer cells between cell survival and cell death induced by autophagy in hypoxia. Autophagy, 2016, 12, 1029-1046.	9.1	86
29	Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia. Leukemia Research, 2016, 50, 63-71.	0.8	7
30	An LC/MS/MS method for the simultaneous determination of individual sphingolipid species in B cells. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1031, 50-60.	2.3	15
31	Comparison of outcome of patients with CLL who are referred or nonreferred to a specialized <scp>CLL</scp> clinic: a Canadian populationâ€based study. Cancer Medicine, 2016, 5, 971-979.	2.8	13
32	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
33	Phosphatidylinositol-3,4-Bisphosphate and Its Binding Protein Lamellipodin Regulate Chemotaxis of Malignant B Lymphocytes. Journal of Immunology, 2016, 196, 586-595.	0.8	15
34	Bcl-2 family member Mcl-1 expression is reduced under hypoxia by the E3 ligase FBW7 contributing to BNIP3 induced cell death in glioma cells. Cancer Biology and Therapy, 2016, 17, 604-613.	3.4	16
35	Incidence and Implications of Skin Cancers in Cancercare Manitoba Chronic Lymphocytic Leukemia (CLL) Clinic Patients. Blood, 2016, 128, 4359-4359.	1.4	0
36	Differential expression and function of CD27 in chronic lymphocytic leukemia cells expressing ZAP-70. Leukemia Research, 2015, 39, 773-778.	0.8	10

#	Article	IF	Citations
37	Differential cellular responses induced by dorsomorphin and <scp>LDN</scp>â€193189 in chemotherapyâ€sensitive and chemotherapyâ€resistant human epithelial ovarian cancer cells. International Journal of Cancer, 2015, 136, E455-69.	5.1	35
38	<scp>ZAP</scp>70 expression directly promotes chronic lymphocytic leukaemia cell adhesion to bone marrow stromal cells. British Journal of Haematology, 2015, 168, 139-142.	2.5	3
39	Hepatitis B and Hepatitis C Viral Infections in Patients with Chronic Lymphocytic Leukemia. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 131-134.	1.9	7
40	On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells. Clinical Cancer Research, 2014, 20, 4861-4872.	7.0	60
41	Poly(ADP-Ribose) Polymerase-1 Causes Mitochondrial Damage and Neuron Death Mediated by Bnip3. Journal of Neuroscience, 2014, 34, 15975-15987.	3.6	45
42	BNIP3 Interacting with LC3 Triggers Excessive Mitophagy in Delayed Neuronal Death in Stroke. CNS Neuroscience and Therapeutics, 2014, 20, 1045-1055.	3.9	194
43	Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway. Leukemia Research, 2014, 38, 109-115.	0.8	14
44	Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells. Apoptosis: an International Journal on Programmed Cell Death, 2014, 19, 191-200.	4.9	22
45	Estrogen Regulation of Anti-Apoptotic Bcl-2 Family Member Mcl-1 Expression in Breast Cancer Cells. PLoS ONE, 2014, 9, e100364.	2.5	27
46	Investigating the Role of Reactive Oxygen Species in Regulating Autophagy. Methods in Enzymology, 2013, 528, 217-235.	1.0	52
47	Starvation-induced autophagy is regulated by mitochondrial reactive oxygen species leading to AMPK activation. Cellular Signalling, 2013, 25, 50-65.	3.6	247
48	Frequent Occurrence of Highly Expanded but Unrelated B-Cell Clones in Patients with Multiple Myeloma. PLoS ONE, 2013, 8, e64927.	2.5	13
49	Targeting Metabolism and Autophagy in the Context of Haematologic Malignancies. International Journal of Cell Biology, 2012, 2012, 1-9.	2.5	15
50	Autophagy in clear cell ovarian cancer, a potential marker for hypoxia and poor prognosis?[#]. Journal of Pathology, 2012, 228, 434-436.	4.5	6
51	Reactive oxygen species regulation of autophagy in cancer: Implications for cancer treatment. Free Radical Biology and Medicine, 2012, 53, 1399-1410.	2.9	137
52	Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 1735-1742.	1.3	42
53	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
54	Regulation of autophagy in hematological malignancies: role of reactive oxygen species. Leukemia and Lymphoma, 2012, 53, 26-33.	1.3	29

#	Article	IF	Citations
55	The Valproic Acid-Fludarabine Combination Induces a Synergistic Response in Chronic Lymphocytic Leukemia Via a Mechanism Involving the Lysosomal Protease Cathepsin B.. Blood, 2012, 120, 2892-2892.	1.4	0
56	Truncated forms of BNIP3 act as dominant negatives inhibiting hypoxia-induced cell death. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 302-311.	3.8	9
57	Death receptor 4 is preferentially recruited to lipid rafts in chronic lymphocytic leukemia cells contributing to tumor necrosis related apoptosis inducing ligand-induced synergistic apoptotic responses. Leukemia and Lymphoma, 2011, 52, 1290-1301.	1.3	18
58	Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2011, 29, 1175-1181.	1.6	134
59	RNA species generated in vaccinia virus infected cells activate cell type-specific MDA5 or RIG-I dependent interferon gene transcription and PKR dependent apoptosis. Virology, 2011, 413, 183-193.	2.4	27
60	Cucurbitacin-I (JSI-124) activates the JNK/c-Jun signaling pathway independent of apoptosis and cell cycle arrest in B Leukemic Cells. BMC Cancer, 2011, 11, 268.	2.6	25
61	Role of BNIP3 in proliferation and hypoxiaâ€induced autophagy: implications for personalized cancer therapies. Annals of the New York Academy of Sciences, 2010, 1210, 8-16.	3.8	29
62	Inhibition of Constitutive Activation of STAT3 by Curcurbitacin-I (JSI-124) Sensitized Human B-Leukemia Cells to Apoptosis. Molecular Cancer Therapeutics, 2010, 9, 3302-3314.	4.1	48
63	A matter of balance between life and death: Targeting reactive oxygen species (ROS)-induced autophagy for cancer therapy. Autophagy, 2010, 6, 835-837.	9.1	84
64	Methods for detecting autophagy and determining autophagy-induced cell deathThis review is one of a selection of papers published in a Special Issue on Oxidative Stress in Health and Disease.. Canadian Journal of Physiology and Pharmacology, 2010, 88, 285-295.	1.4	96
65	Epidermal Growth Factor (EGF) Receptor Signaling and Cancer. , 2010, , 119-141.		1
66	BNIP3 (Bcl-2 19 kDa Interacting Protein) Acts as Transcriptional Repressor of Apoptosis-Inducing Factor Expression Preventing Cell Death in Human Malignant Gliomas. Journal of Neuroscience, 2009, 29, 4189-4199.	3.6	46
67	RIGging functional outcomes in glioma cells: New insights into LRIG proteins in malignant gliomas. Cancer Biology and Therapy, 2009, 8, 1024-1026.	3.4	2
68	Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression. Leukemia and Lymphoma, 2009, 50, 2038-2048.	1.3	13
69	Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro. British Journal of Haematology, 2009, 147, 396-398.	2.5	12
70	Investigation of an NQO1 polymorphism as a possible risk and prognostic factor for chronic lymphocytic leukemia. Leukemia Research, 2009, 33, 74-81.	0.8	7
71	Regulation of Autophagy by Reactive Oxygen Species (ROS): Implications for Cancer Progression and Treatment. Antioxidants and Redox Signaling, 2009, 11, 777-790.	5.4	674
72	TAPP2 links phosphoinositide 3-kinase signaling to B-cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B-cell leukemia. Blood, 2009, 114, 4703-4712.	1.4	25

#	Article	IF	Citations
73	Death receptor-4 (DR4) expression is regulated by transcription factor NF-Î²B in response to etoposide treatment. Apoptosis: an International Journal on Programmed Cell Death, 2008, 13, 756-770.	4.9	44
74	Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. British Journal of Haematology, 2008, 143, 698-706.	2.5	59
75	Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies. Cellular Signalling, 2008, 20, 1198-1208.	3.6	23
76	Brevininâ€2R¹ semiâ€selectively kills cancer cells by a distinct mechanism, which involves the lysosomalâ€mitochondrial death pathway. Journal of Cellular and Molecular Medicine, 2008, 12, 1005-1022.	3.6	151
77	The role of TRAIL death receptors in the treatment of hematological malignancies. Leukemia and Lymphoma, 2008, 49, 27-35.	1.3	39
78	Is mitochondrial generation of reactive oxygen species a trigger for autophagy?. Autophagy, 2008, 4, 246-248.	9.1	215
79	Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy, 2008, 4, 151-175.	9.1	2,064
80	Lysophosphatidic Acid Protects Cancer Cells from Histone Deacetylase (HDAC) Inhibitor-induced Apoptosis through Activation of HDAC. Journal of Biological Chemistry, 2008, 283, 16818-16829.	3.4	32
81	Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy, 2008, 4, 195-204.	9.1	321
82	Mitochondrial electron-transport-chain inhibitors of complexes I and II induce autophagic cell death mediated by reactive oxygen species. Journal of Cell Science, 2007, 120, 4155-4166.	2.0	394
83	Regulation of apoptosis in fibroblastâ€like synoviocytes by the hypoxiaâ€induced Bclâ€2 family member Bclâ€2/adenovirus E1B 19â€kd proteinâ€interacting protein 3. Arthritis and Rheumatism, 2007, 56, 2854-2863.	6.7	34
84	Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer. Biologics: Targets and Therapy, 2007, 1, 229-39.	3.2	5
85	The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1175-1193.	4.9	84
86	Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: Implications for cancer therapy. Cellular Signalling, 2006, 18, 2089-2097.	3.6	257
87	The pro-cell death Bcl-2 family member, BNIP3, is localized to the nucleus of human glial cells: Implications for glioblastoma multiforme tumor cell survival under hypoxia. International Journal of Cancer, 2006, 118, 1660-1669.	5.1	81
88	Herceptin Sensitizes ErbB2â€Overexpressing Cells to Apoptosis by Reducing Antiapoptotic Mcl-1 Expression. Clinical Cancer Research, 2006, 12, 845-853.	7.0	74
89	The Vascular Endothelial Growth Factor (VEGF) Autocrine Survival Signaling Pathway in Chronic Lymphocytic Leukemia (CLL) Is Regulated by Lysophosphatidic Acid (LPA).. Blood, 2006, 108, 2810-2810.	1.4	0
90	Younger Patients with CLL/SLL Are Less Frequent and Have Favorable Survival in a Canadian Population Based Study: The Manitoba Cohort.. Blood, 2006, 108, 3335-3335.	1.4	6

#	Article	IF	Citations
91	Growth Factors, Receptors, and Kinases: Their Exploration to Target Cancer. , 2005, , 173-195.		3
92	Lysophosphatidic Acid (LPA) Protects Primary Chronic Lymphocytic Leukemia Cells from Apoptosis through LPA Receptor Activation of the Anti-apoptotic Protein AKT/PKB. Journal of Biological Chemistry, 2005, 280, 9498-9508.	3.4	51
93	Transcription Factor NF-Î²B Differentially Regulates Death Receptor 5 Expression Involving Histone Deacetylase 1. Molecular and Cellular Biology, 2005, 25, 5404-5416.	2.3	136
94	The S100A7-c-Jun Activation Domain Binding Protein 1 Pathway Enhances Prosurvival Pathways in Breast Cancer. Cancer Research, 2005, 65, 5696-5702.	0.9	69
95	The Two Faces of NF?B in Cell Survival Responses. Cell Cycle, 2005, 4, 1342-1345.	2.6	53
96	Cyclin D expression in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2005, 46, 1275-1285.	1.3	11
97	MEKK1-induced apoptosis is mediated by Smac/Diablo release from the mitochondria. Biochemical and Biophysical Research Communications, 2005, 331, 1089-1098.	2.1	10
98	Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. Journal of Cell Science, 2005, 118, 4485-4493.	2.0	103
99	The Role of Histone Acetylation and Death Receptor 5 (DR5) Expression in the Treatment of Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 5017-5017.	1.4	0
100	The Role of Proteasome Inhibitors and the Trail Apoptotic Pathway in the Treatment of Chronic Lymphocytic Leukemia.. Blood, 2005, 106, 5011-5011.	1.4	0
101	BNIP3 Expression Is Linked with Hypoxia-Regulated Protein Expression and with Poor Prognosis in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 5566-5571.	7.0	129
102	Role of Myeloid Cell Factor-1 (Mcl-1) in Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 2004, 45, 2017-2027.	1.3	34
103	Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications. Current Cancer Drug Targets, 2004, 4, 147-163.	1.6	44
104	Proteasome Inhibiters Up-Regulate TRAIL/Apo2L and Its Receptors Significantly Contributing to Proteasome Inhibitor-Induced Apoptosis in Primary Chronic Lymphocytic Leukemia (CLL) Cells.. Blood, 2004, 104, 2810-2810.	1.4	20
105	Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway. Journal of Cellular Biochemistry, 2003, 89, 1177-1192.	2.6	65
106	BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene, 2003, 22, 4734-4744.	5.9	199
107	Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene, 2003, 22, 8356-8369.	5.9	57
108	MEK Kinase 1 Induces Mitochondrial Permeability Transition Leading to Apoptosis Independent of Cytochrome cRelease. Journal of Biological Chemistry, 2002, 277, 10573-10580.	3.4	15

#	Article	IF	Citations
109	MEKK1-induced apoptosis requires TRAIL death receptor activation and is inhibited by AKT/PKB through inhibition of MEKK1 cleavage. Oncogene, 2002, 21, 6649-6656.	5.9	18
110	Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release. Cancer Research, 2002, 62, 488-96.	0.9	93
111	Increased Expression of Death Receptors 4 and 5 Synergizes the Apoptosis Response to Combined Treatment with Etoposide and TRAIL. Molecular and Cellular Biology, 2000, 20, 205-212.	2.3	249
112	Reovirus-Induced Apoptosis Is Mediated by TRAIL. Journal of Virology, 2000, 74, 8135-8139.	3.4	186
113	Mitogen-Activated Protein Kinase: Conservation of a Three-Kinase Module From Yeast to Human. Physiological Reviews, 1999, 79, 143-180.	28.8	2,492
114	MEK Kinase 1 (MEKK1) Transduces c-Jun NH2-terminal Kinase Activation in Response to Changes in the Microtubule Cytoskeleton. Journal of Biological Chemistry, 1999, 274, 12605-12610.	3.4	115
115	Epidermal Growth Factor Protects Epithelial Cells against Fas-induced Apoptosis. Journal of Biological Chemistry, 1999, 274, 17612-17618.	3.4	225
116	Differential Involvement of MEK Kinase 1 (MEKK1) in the Induction of Apoptosis in Response to Microtubule-targeted Drugsversus DNA Damaging Agents. Journal of Biological Chemistry, 1999, 274, 10916-10922.	3.4	62
117	Anti-apoptotic versus pro-apoptotic signal transduction: Checkpoints and stop signs along the road to death. Oncogene, 1998, 17, 1475-1482.	5.9	153
118	Caspase-dependent Cleavage of Signaling Proteins during Apoptosis. Journal of Biological Chemistry, 1998, 273, 7141-7147.	3.4	374
119	Efficient CD28 signalling leads to increases in the kinase activities of the TEC family tyrosine kinase EMT/ITK/TSK and the SRC family tyrosine kinase LCK. Biochemical Journal, 1998, 330, 1123-1128.	3.7	24
120	Lysophosphatidylcholine Stimulates Activator Protein 1 and the c-Jun N-terminal Kinase Activity. Journal of Biological Chemistry, 1997, 272, 13683-13689.	3.4	69
121	Functional LCK Is Required for Optimal CD28-mediated Activation of the TEC Family Tyrosine Kinase EMT/ITK. Journal of Biological Chemistry, 1996, 271, 7079-7083.	3.4	68